BCR and prostate adenocarcinoma: Finally, we established a cutpoint for the preoperative PSA concentration of 6.9 ng/mL, which significantly differentiated BCR-free survival among the PRAD cohort (HR = 1.93, 95% CI = 1.15–3.25, p = 0.012).